HSV can cause oral lesions that exacerbate chemotherapy-related mucositis. Intravenous acyclovir is effective in preventing HSV reactivations, but expensive. Valacyclovir has good bioavailability and has not been studied for prophylaxis of HSV among PCT patients. We compared the efficacy and costs of valacyclovir in preventing HSV reactivation among HSV seropositive autologous progenitor cell transplantation (APCT) patients with historical controls in whom intravenous acyclovir or no HSV prophylaxis were used. Valacyclovir group: From October 1997 to April 1999 108 adult patients received valacyclovir 500 mg twice daily from day −3 of APCT until neutropenia recovery or day +30. Valacyclovir was switched to intravenous acyclovir in cases of oral intolerance (17 patients) or suspected HSV reactivation (five patients). Intravenous acyclovir group: From January 1996 to October 1997 43 patients received 5 mg/kg twice-daily intravenous acyclovir from day −3 until recovery from neutropenia. No prophylaxis group: 38 patients from January 1996 to October 1997 did not receive HSV prophylaxis. HSV reactivations were seen in 2.7%, 2% and 45% of patients in the valacyclovir, intravenous acyclovir, and no prophylaxis groups, respectively. Valacyclovir was well tolerated and was the least expensive strategy. Oral valacyclovir was as effective as intravenous acyclovir for the prophylaxis of HSV reactivation in APCT patients.
In immunocompromised patients Herpes simplex virus (HSV) can cause severe oral lesions, esophagitis, tracheobronchitis, and pneumonitis. It has been reported that 70 to 80% of patients who undergo autologous or allogeneic bone marrow transplantation and test positive for HSV antibodies reactivate the HSV infection. 1 Intravenous acyclovir (i.v. ACY) is effective in preventing HSV reactivation 2,3 but expensive. Oral ACY is also effective 4 and less expensive but due to its low bioavailability, patients need to receive high doses (1200 to 1400 mg/day). 5 This dose of oral ACY requires several pills a day and poor compliance due to the concomitant occurrence of chemotherapy-induced mucositis may result.
Valacyclovir (VAL), is an oral prodrug of acyclovir and its bioavailability is three times higher than oral acyclovir. 6 It is less expensive than i.v. ACY and is effective in suppressing genital HSV recurrences in HIV 7 and immunocompetent patients. 8 We compared the efficacy and costs of VAL in preventing HSV reactivation among our autologous progenitor cell transplantation (APCT) patients with historical controls in whom i.v. ACY or no HSV prophylaxis (NP) were used.
Materials and methods

VAL group
From October 1997 to October 1999 all APCT patients Ͼ12 years old who tested (+) for HSV Ig G antibodies by indirect immunofluorescence received VAL (Valtrex; Glaxo-Wellcome, Argentina) 500 mg p.o. twice daily from day −3 of PCT until recovery from neutropenia, day +30 of APCT, severe toxicity, or HSV reactivation, which ever came first. VAL was switched to i.v. ACY (acyclovir, Filaxis, Argentina) prophylaxis (5 mg/kg twice a day daily) in cases of oral intolerance, or to i.v. ACY treatment (5 mg/kg three times daily), in cases of HSV reactivation. Patients receiving i.v. ACY prophylaxis due to oral intolerance were switched back to p.o. VAL when they recovered from the oral intolerance. Patients were followed every day by an infectious diseases specialist (MCD or AM) and every other day by a dentist (MM). Patients who developed ulcerative oral or genital lesions underwent viral cultures.
i.v. ACY group
From January 1996 to Ocrover 1997 all APCT patients who tested (+) for HSV Ig G antibodies and received other conditioning treatments than cyclophosphamide, BCNU and VP-16, received i.v. ACY 5 mg/kg twice daily from day −3 until recovery from neutropenia.
NP group
From January 1996 to October 1997 APCT patients who tested (+) for HSV Ig G antibodies and received conditioning treatment with cyclophosphamide, BCNU and VP-16 did not receive any HSV prophylaxis because they were expected to develop less severe mucositis than recipients of other conditioning regimens.
Viral cultures
Viral cultures were carried out using conventional cultures (CC) and shell vial assays (SV). 9 Clinical specimens were inoculated on to monolayers of human foreskin fibroblasts and tested for the rapid diagnosis of HSV infections by detection of cytophatic effect (for CC, for 7 days) and by using fluoresceinated monoclonal antibodies anti-HSV, (Imagen, Dako) (for SV, 24 h post inoculation).
Definition of HSV reactivation
We defined HSV reactivation when ulcerative oral or genital lesions were present and cultured (+) for HSV. When viral cultures were not available, the diagnosis of HSV reactivation was made clinically by the assessment of two investigators. Statistical analysis: Statistical analysis of dichotomous variables was done by the chi-square test (Yates corrected), Fisher's exact test or Wilk's test (log likelihood test). Continuous variables were treated using the Kruskal-Wallis non-parametric test and Mann-Whitney U test. To estimate the multivariable predictive value of independent covariates, stepwise multiple logistic regression models were used. Degree of fit of data to each model was estimated by the Hosmer-Lemeshow test, and the percentage of the variance was obtained. The predictive value for each significant covariant was expressed as the odds ratio (OR), obtained from the beta coefficient of each model. A 95% confidence interval (CI) was derived as the standard error of these beta coefficients. Statistical significance was taken as P Ͻ 0.05, two-sided.
Results
A total of 189 patients were included in the study. Of these, 108 received p.o. VAL (VAL group), 43 patients received i.v. ACY (i.v. ACY group), and 38 did not receive any HSV prophylaxis (NP group). Patient characteristics are shown in Table 1 .
Duration of treatments and compliance
VAL group: Patients received VAL prophylaxis for a median of 14 days (range, 1-26). Reasons for VAL discontinuation are shown in Table 2 . The most common reason for discontinuing VAL was end of prophylaxis (78%). Oral intolerance secondary to mucositis was seen in 17 (15%) patients. All these patients were then switched to i.v. ACY for a median of 5.5 days (range, 2-15) and five (29%) of them were switched back to VAL when the mucositis resolved. VAL was switched to i.v. ACY treatment due to suspected HSV reactivation in five (5%) patients, although definite HSV reactivation was confirmed in three of them. Forty percent of patients developed oral or genital lesions that required viral cultures to be taken. VAL was well tolerated. In one patient, VAL was discontinued due to severe rash, although no casual relationship to the study drug could be established.
i.v. ACY group:
Patients received i.v. ACY prophylaxis for a median of 15 days (range, 7-38). In one patient (2%) the dose of i.v. ACY was increased due to HSV reactivation, and in no case did i.v. ACY have to be discontinued due to toxicity. Twelve percent of patients developed oral or genital lesions that required viral cultures to be taken.
NP group: Sixty percent of patients developed oral or genital lesions that required viral cultures to be taken. i.v. ACY was used for treatment of HSV reactivation in 17 (45%) patients.
Efficacy of treatments
VAL group: The efficacy of each strategy of prophylaxis for HSV reactivation is shown in Table 3 . Three (2.7%) mild genital HSV reactivations developed in the VAL group. These breakthrough genital HSV reactivations were diagnosed clinically (one was not cultured and two cultured negative for HSV) and all responded to i.v. ACY. Of note, one patient had nonspecific genital lesions that cultured (−) for HSV by the SV assay but became (+) by the CC. By the time the CC became (+) the lesions had already resolved, and the VAL prophylaxis was therefore not switched to i.v. ACY. This case was not included in the NP group: Seventeen (45%) HSV reactivations were seen in the NP group. Of these, three were diagnosed clinically and 14 cultured positive for HSV. Of note, and in contrast to the VAL group, only 17% included genital reactivations. Multivariate analysis of risk factors showed that not receiving any drug was an independent risk factor for HSV reactivation (OR 36.4, 95% confidence 7.1 to 185, P Ͻ 0.0001). VAL and i.v. ACY were shown to be equally effective for the prevention of HSV reactivation (P = NS). Due to the potentially different incidence of HSV reactivation according to underlying disease and treatment regimen, we decided to analyze the development of HSV reactivation among patients with the same underlying disease. We found that VAL was still significantly better than no prophylaxis and as equally effective as i.v. ACY for the prophylaxis of HSV reactivation among APCT recipients. Among patients with lymphoma (n = 91), 15/29 of the NP group and 2/62 of the VAL group developed HSV reactivation (OR 32.1, 95% confidence 5.9-232, P Ͻ 0.0000002). Among patients with leukemia and multiple myeloma (n = 78), 1/41 of the i.v. ACY group and 1/37 of the VAL group developed HSV reactivation (P = 0.999, NS).
Costs
The costs associated with each of the three strategies are shown in Table 4 . VAL was 1010 U$S less expensive per patient than i.v. ACY. VAL was also associated with less costs (209 U$S less expensive per patient) than the NP strategy. In our institution VAL prophylaxis in PCT patients implies an annual saving of 60 600 U$S (average 60 PCT per year) compared to i.v. ACY.
Discussion
Our study showed that VAL at a dose of 500 mg p.o. twice daily started on day −3 of APCT was well tolerated, and Table 4 Costs associated with each strategy for prophylaxis of HSV reactivation as effective as, and less expensive than i.v. ACY in preventing HSV reactivation among patients undergoing APCT. We also showed the VAL prophylaxis strategy to be less expensive and more effective than the non-prophylaxis strategy.
To our knowledge, this is the first report of VAL for prophylaxis of HSV in APCT patients. There is no standardized dose for this use. We chose the dose of 500 mg twice a day because it was effective in preventing genital HSV reactivations in other immunocompromised patients. 7 In the VAL group, breakthrough HSV reactivations developed in 3% of APCT patients. In all cases, these were mild and all responded to i.v. ACY. Of note, in our VAL group HSV breakthrough reactivations were 100% genital. This presentation differed from the one observed in the NP group (88% oral, 17% genital), and from the one reported in the literature. Oral HSV usually accounts for 85% of presentations, 10 while the genital or perianal localization accounts for the remaining 10 to 15%. Since we do not know whether HSV-1 or HSV-2 caused the genital lesions, we cannot make any hypothesis.
We acknowledge that this study had some limitations. It was non-blinded, non-randomized, and it used an historical control group. However, the bias that could have emerged as a result of using an historical control was reduced by the homogeneity of the groups. All patients belonged to the same institution, underwent the same procedure (ASCT), received the same intensity of medical support, and were evaluated by the same investigators. All groups had the same risk of developing the study endpoint. There was a difference in the number of viral cultures taken in different groups (more in the VAL group compared to the i.v. ACY group). This difference was secondary to the fact that VAL was a new drug of unknown efficacy under study, while i.v. ACY was an old drug with an already known efficacy. However, if this difference resulted in a bias in the conclusion of the study, it would have been against the VAL group.
Our findings are comparable to those reported with oral acyclovir prophylaxis. 4 Wade et al 4 observed a decreased incidence of HSV reactivation from 70% in the placebo group to 20% in the acyclovir group using a dose of 2400 mg/day. We observed a reduction in the incidence of HSV reactivation from 45% in the historical NP group to 3% in the VAL at a dose of 1000 mg/day.
The potential development of a thrombotic microangiopathy-like syndrome (TMA) secondary to VAL administration is of concern.
11 We did not see such a case after 1405 days of VAL administration among 108 patients at a dose of 1000 mg/day. This is in agreement with other reports of VAL prophylaxis for CMV in 376 BMT patients using a dose of 8000 mg/day. 12 Compliance was acceptable. Despite the presence of chemotherapy-induced mucositis, and the big size of the pills, 78% of patients could continue oral VAL until the end of prophylaxis.
During the last years, costs have become an important factor to be included in any medical decision for treatment or diagnosis. Even though this study was not designed as a cost-effectiveness study, we did look back at our costs after the study was finished. We found that in our institution VAL prophylaxis implied a significant saving compared to either i.v. ACY (60 600 U$S savings per year) or even NP (12 540 U$S savings per year). Currently, savings of the VAL strategy compared to i.v. ACY may be even higher because after knowing the results of this study, we reduced the number of viral cultures taken from oral ulcerative lesions. Likewise, current savings of VAL prophylaxis compared to NP may be higher in the setting of a higher incidence of HSV reactivation.
Many questions remain unanswered. What is the appropriate dose for HSV prophylaxis in APCT patients? Should autologous and allogeneic PCT patients receive the same VAL dose? Why were all VAL-breakthrough HSV reactivations genital?
In conclusion, our findings showed that VAL 500 mg twice daily may be considered as a safe and less expensive alternative to i.v. ACY for prophylaxis of HSV in APCT patients. These findings should be confirmed in a prospective trial directed towards assessing efficacy, safety, and appropriate dosing.
